In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

People living with Alzheimer’s dementia — the forgetfulness, the confusion, and the ultimate erasure of identity — and their families pushed hard for the Food and Drug Administration to approve ...

An influential, independent panel unanimously voted that aducanumab (Aduhelm) offers no benefit for patients with Alzheimer's disease (AD), adding to growing opposition from medical experts to the US ...

With incomplete data to guide aducanumab (Aduhelm) prescribing, neurologists face ethical challenges and will be guided best by established principles to counsel people with Alzheimer's disease and ...

Controversy has swirled around aducanumab, an experimental drug developed by Biogen, long before the FDA approved it on Monday to treat early-stage Alzheimer’s disease. The agency now finds itself ...

Not all physicians who treat Alzheimer's disease will prescribe the new Alzheimer's drug aducanumab (Aduhelm) -- major hospital systems like the Cleveland Clinic and Mount Sinai in New York City, for ...

Aducanumab (Aduhelm), the only monoclonal antibody approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer's disease (AD), removes amyloid from the brain and reduces ...

In June, the Food and Drug Administration (FDA) approved aducanumab, the first new treatment for Alzheimer’s disease in 18 years. But the medication, which is produced by Biogen under the name Aduhelm ...